Standard-Dose Tenecteplase vs Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion: A Randomized Clinical Trial.

JAMA Neurol · 2026 · PMC13227334 · PMID 42223935

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

Our meta-analysis further supported this, showing a marginally significant increase in substantial reperfusion with tenecteplase.

also in 26,082 other papers

did not reach statistical significanceno p-value reported

Secondary efficacy outcomes, including functional outcomes at 90 days and early neurological improvement at 72 hours, were numerically superior in the tenecteplase group to the alteplase group, although these differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.